| Literature DB >> 25103204 |
Yi Wang1, Melissa N Eliot2, Gregory A Wellenius2.
Abstract
BACKGROUND: Stroke is a leading cause of death and long-term disability in the United States. There is a well-documented association between ambient particulate matter air pollution (PM) and cardiovascular disease morbidity and mortality. Given the pathophysiologic mechanisms of these effects, short-term elevations in PM may also increase the risk of ischemic and/or hemorrhagic stroke morbidity and mortality, but the evidence has not been systematically reviewed. METHODS ANDEntities:
Keywords: air pollution; cerebrovascular disease; meta‐analysis; particulate matter; stroke
Mesh:
Substances:
Year: 2014 PMID: 25103204 PMCID: PMC4310387 DOI: 10.1161/JAHA.114.000983
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1.Search strategy and rationale for excluding 15 studies. CBVD indicates cerebrovascular disease; PM, particulate matter; TIA, transient ischemic attack.
Description of 29 Studies of Associations Between Short‐term Exposure to PM and Hospital Admission for CBVD or Ischemic or Hemorrhagic Stroke
| Source | Location | Design | Outcome/Number of Daily Events | Outcome Source | N | Age (y) | Mean Exposure Level (μg/m3) | Lag (d) | % Change in Observed Effect (95% CI) |
|---|---|---|---|---|---|---|---|---|---|
| PM2.5 | |||||||||
| Dominici et al[ | 204 urban counties, US | T | CBVD (ICD‐9: 430 to 438)/5.4 | A | 11.5 million | 75+, 65 to 74, 65+ | 13.4 | 0 | 0.8% (0.3% to 1.3%) to 2.1% (0.6% to 3.6%) |
| Lisabeth et al[ | Nueces County, TX | T | Ischemic stroke and TIA/2 | M | 3508 | 45+ | 7 | 0, 1 | 6.0% (−1.7% to 14.2%) |
| Delfino et al[ | Southern CA, US | T | CBVD (ICD‐9: 430 to 438)/NA | A | 10 438 | 45+ | NA | NA | 1.9% (0.3% to 3.5%) |
| Peng et al[ | 108 urban counties, US | T | CBVD (ICD‐9: 430 to 438)/NA | A | NA | 75+, 65 to 74, 65+ | 13.5 | 0, 1, 2 | NA |
| O'Donnell et al[ | Ontario, Canada | C | Ischemic stroke and TIA (TOAST)/NA | M | 9202 | All ages | 6.9 | 0–1 | −0.7% (−6.2% to 5.1%) |
| Wellenius et al[ | Boston, MA | C | Ischemic stroke/NA | M | 1705 | 21+ | NA | 0 | 17.7% (4.2% to 33.0%) |
| PM10 | |||||||||
| Wong et al[ | Hong Kong | T | CBVD (ICD‐9: 430 to 438)/NA | A | NA | All ages | 44.99 | 2 | 0.3% (−0.4% to 1.0%) |
| Wordley et al[ | Bringmingham, England | T | CBVD (ICD‐9: 430 to 436)/6.6 | A | NA | All ages | 25.6 | 0 | 2.1% (0.1% to 4.1%) |
| Le Tertre et al[ | Eight cities, Europe | T | CBVD (ICD‐9: 430 to 438)/NA | A | NA | 65+ | NA | 0–1 | 0% (−0.3% to 0.3%) |
| Tsai et al[ | Kaohsiung, Taiwan | C | Ischemic stroke (ICD‐9: 433 to 435)/8.73 | A | 12 758 | All ages | 78.82 | 0–2 | −0.5% (−6.2% to 5.7%), 5.9% (4.3% to 7.4%) |
| Wellenius et al[ | 9 cities, US | C | Ischemic stroke/NA | A | 155 503 | 65+ | 28.36 | 0 | 0.4% (0% to 0.9%) |
| Hemorrhage/NA | 19 314 | 65+ | 28.36 | 0 | −0.3% (−2.4% to 2.0%) | ||||
| Henrotin et al[ | Dijon, France | C | Ischemic stroke (TOAST)/NA | M | 762 | 40+ | 21.1 | 0, 1, 2, 3 | −4.0% (−11.0% to 3.6%) to 1.1% (−6.6% to 9.4%) |
| Hemorrhage (TOAST)/NA | 99 | 40+ | 21.1 | 0, 1, 2, 3 | −9.9% (−26.9% to 11.1%) to 10% (−9.6% to 33.9%) | ||||
| Larrieu et al[ | Eight cities, France | T | Stroke (ICD‐10: 60 to 64, G45 to 46)/34.4 | A | 11 105 389 | All ages | 21.0 to 28.9 | 0–1 | 0.2% (−1.5% to 1.9%) |
| Stroke (ICD‐10: 60 to 64, G45 to 46)/24.9 | 11 105 389 | 65+ | 21.0 to 28.9 | 0–1 | 0.8% (−0.9% to 2.5%) | ||||
| Vidale et al[ | Como, Italy | T | Ischemic stroke/0.73 | M | 759 | All | NA | 0, 1, 2, 3, 4, 5 | NA |
| Andersen et al[ | Copenhagen, Denmark | C | Ischemic stroke (SSS)/NA | M | 6798 | All ages | 27.1 | 0, 1, 2, 3, 4, 0–4 | −3.9% (−11.5% to 6.5%) to 8.7% (−0.9% to 19.3%) |
| Hemorrhage (SSS)/NA | 585 | All ages | 27.1 | 0, 1, 2, 3, 4, 0–4 | −3.9% (−11.6% to 6.5%) to 13.3% (2.3% to 25.5%) | ||||
| Bedata et al[ | Manchester and Liverpool, England | C | Minor stroke+TIA/NA | M | 709 | All | 22.6/20.6 | 0, 1, 2, 3 | −8.8% (−15.6% to 1.3%) to 12.9% (−1.3% to 29.2%) |
| Corea et al[ | Mantua, Italy | C | CBVD/NA | M | 781 | All | NA | 0 | NA |
| Ischemic stroke/NA | 567 | All | NA | 0 | NA | ||||
| Hemorrhage/NA | 106 | All | NA | 0 | NA | ||||
| TIA/NA | 108 | All | NA | 0 | NA | ||||
| Nascimento et al[ | Sao Jose dos Campos, Brazil | T | Stroke (ICD‐10: 60 to 64)/0.8 | A | 407 | All | 24.4 | 0, 1, 2 | 0.5% (−0.4% to 1.4%)to 1.4% (0.5% to 2.3%) |
| Oudin et al[ | Scania, Sweden | C | Ischemic stroke/6 | M | 11 267 | All | 16.3 | 0–1 | NA |
| Zheng et al[ | Lanzhou, China | T | CBVD (ICD‐9: 430 to 438)/6 | A | 28 243 | All | 187.07 | 0, 1, 2, 3, 0–1, 0–2, 0–3 | −0.1% (−0.3% to 0.1%) |
| PM2.5‐10+PM2.5 | |||||||||
| Halonen et al[ | Helsinki, Finland | T | Stroke (ICD‐10: I60 to 61, I63 to 64)/4 | A | 10 383 | 65+ | 9.5 | 0, 1, 2, 3, 0–4 | −2.2% (−5.0% to 0.6%) to 0% (−2.8% to 3.0%) |
| PM10+PM2.5 | |||||||||
| Chan et al[ | Taipei, Taiwan | T | CBVD (ICD‐9: 430 to 437)/1.0 | A | 7341 | 50+ | PM10 (50.2) | 0, 1, 2, 3 | 0% (−1.2% to 1.3%) to 1.2% (0.4% to 1.9%) |
| Stroke (ICD‐9: 430 to 434)/3.5 | 2184 | 50+ | PM2.5 (31.5) | −3.6% (−8.9% to 2.1%) to 1.1% (0.3% to 1.9%) | |||||
| Ischemic stroke (ICD‐9: 433 to 434)/0.7 | 1494 | 50+ | PM10 (50.2) | −1.4% (−4.5% to 1.9%) to 0.1% (−3.0% to 3.2%) | |||||
| PM2.5 (31.5) | −6.8% (−3.6% to 0.5%) to −4.1% (−8.6% to 0.5%) | ||||||||
| Hemorrhage (ICD‐9: 430 to 432)/0.3 | 690 | 50+ | PM10 (50.2) | −0.6% (−2.6% to 1.4%) to 1.6% (−0.6% to 3.9%) | |||||
| PM2.5 (31.5) | −2.1% (−5.7% to 1.8%) to 3.0% (−0.6% to 6.6%) | ||||||||
| Jalaludin et al[ | Sydney, Australia | T | CBVD (ICD‐9: 430 to 438)/11.3 | A | NA | 65+ | PM10 (16.8) | 0, 1, 2, 3, 0−1 | −2.6% (−4.9% to −0.3%) to −1.6% (−4.0% to 0.8%) |
| PM2.5 (9.5) | −3.1% (−6.3% to −0.3%) to −2.2% (−5.2% to 0.9%) | ||||||||
| Villeneuve et al[ | Edmonton, Canada | C | Ischemic stroke (ICD‐9: 434, 436)/NA | A | 4850 | 65+ | PM10 (24.2) | 0, 1, 0–2 | −1.3% (−4.3% to 1.9%) to 0% (−3.0% to 3.1%) |
| PM2.5 (8.5) | 0% (−7.5 to 8.1%) to 0% (−6.0% to 6.4%) | ||||||||
| Hemorrahage (ICD‐9: 430, 432)/NA | 2329 | 65+ | PM10 (24.2) | 0.6% (−5.7% to 7.3%) to 1.9% (−4.9% to 9.1%) | |||||
| PM2.5 (8.5) | −1.6% (−14.3% to 13.0%) to 11.3% (−2.1% to 26.6%) | ||||||||
| TIA (ICD‐9: 435)/NA | 4855 | 65+ | PM10 (24.2) | −3.8% (−8.0% to 0.6%) to −0.6% (−4.2% to 3.1%) | |||||
| Bell et al[ | Taipei, Taiwan | T | CBVD (ICD‐9: 430 to 437)/3.9 | A | 11 466 | All ages | PM10 (49.1) | 0, 1, 2, 3, 0–3 | −0.7% (−1.6% to 0.1%) to 0.9% (0.1% to 1.8%) |
| PM2.5 (31.6) | −0.7% (−2.8% to 1.4%) to 0.6% (−0.7% to 1.9%) | ||||||||
| PM2.5 (8.5) | −6.3% (−16.2% to 4.8%) to −1.6% (−9.0% to 6.4%) | ||||||||
| Mechtouff et al[ | Lyon, France | C | Ischemic stroke/1.8 | M | 376 | All | PM10 (31.6) | 0–1, 0–2, 0–3, 0–4 | −3.9% (−13.0% to 6.3%) |
| PM2.5 (23.8) | −2.9% (−15.6% to 11.5%) | ||||||||
| PM10+PM2.5‐10+PM2.5 | |||||||||
| Lippmann et al[ | Detroit, US | T | Stroke (ICD‐9: 431 to 437)/13 | A | NA | 65+ | PM10 (31) | 0, 1 | 0.9% (−1.1% to 3.0%) |
| PM2.5 (18) | 0.7% (−2.2% to 3.7%) | ||||||||
| PM2.5‐10 (13) | 1.9% (−1.9% to 5.9%) | ||||||||
| Anderson et al[ | Midland area, England | T | CBVD (ICD‐9: 430 to 438)/NA | M | NA | 65+ | PM10 (23.3) | 0–1 | −1.4% (−3.3% to 0.6%), |
| PM2.5 (14.5) | −0.9% (−3.7% to 2.0%), | ||||||||
| PM2.5‐10 (14.6) | 6.0% (−1.7% to 14.2%) | ||||||||
| Alessandrini et al[ | Rome, Italy | T | CBVD (ICD‐9: 430 to 438)/NA | A | 26 557 | 35+ | PM10 (37) | 0 | 0.5% (−1.2% to 2.1%) |
| PM2.5 (23.4) | 1.1% (−1.8% to 4.2%) | ||||||||
| PM2.5‐10 (14.6) | −2.2% (−4.4% to 0%) | ||||||||
A indicates administrative records; C, case‐crossover; CBVD, cerebrovascular disease; M, medical record review; PM, particulate matter; T, time‐series.
Per 10 μg/m3 increase in pollutant levels.
Description of 16 Studies of Associations Between Short‐term Exposure to PM and Mortality for CBVD Mortality Based on Death Certificate
| Source | Location | Design | Outcome | Daily Number of Events | N | Age (y) | Mean Exposure Level (μg/m3) | Lag (d) | % Change in Observed Effect (95% CI) |
|---|---|---|---|---|---|---|---|---|---|
| PM2.5 | |||||||||
| Franklin et al[ | 27 communities, US | C | CBVD (ICD‐9: 430 to 438) | NA | 95 687 | All ages | 15.7 | 0, 1, 0–1 | 1.0% (0% to 2.0%) |
| Yorifuji et al[ | Tokyo, Japan | T | CBVD (ICD‐10: 60 to 61, 63, 69.0 to 69.3) | 19.7 | 41 440 | All ages | 21.6 | 0, 1, 2, 0–1, 0–2 | −0.2% (−1.2% to 0.8%) to 1.3% (0.2% to 2.4%) |
| Subarachnoid hemorrhage (ICD‐10: 60, 69.3) | 2.4 | 0.9% (−1.9% to 3.8%) to 4.3% (0.4% to 8.4%) | |||||||
| Intracerebral hemorrhage (ICD‐10: 61, 69.1) | 5.6 | −1.4% (−3.4% to 0.6%) to 1.2% (−0.9% to 3.3%) | |||||||
| Ischemic stroke (ICD‐10: 63, 69.3) | 11.7 | −0.3% (−1.7% to 1.1%) to 1.4% (0% to 2.8%) | |||||||
| PM10 | |||||||||
| Hong et al[ | Seoul, Korea | T | CBVD (ICD‐10: 60 to 69) | 15.3 | NA | All ages, 65+, 65− | 71.1 | 0 | 0% (−1.7% to 1.6%) to 1.0% (−0.3% to 2.2%) |
| Wong et al[ | Hong Kong, China | T | CBVD (ICD‐9: 430 to 438) | NA | NA | All ages | 9 | 2 | 0.7% (−0.2% to 1.6%) |
| Kan et al[ | Shanghai, China | T | CBVD (ICD‐9: 430 to 438) | 3.3 | 2426 | All ages | 97 | 1 | 0.8% (0% to 1.6%) |
| Kim et al[ | Seoul, Korea | T | CBVD (ICD‐10: 60 to 69) | 15 | NA | All ages | 69.2 | 0, 1, 2 | 0.6% (0.1% to 1.0%) to 0.7% (0.2% to 1.2%) |
| Qian et al[ | Wuhan, China | T | CBVD (ICD‐9: 430 to 438) | 14 | 20 409 | 65+ | 141.8 | 0, 1, 0–1, 0–4 | 0.3% (−0.2% to 0.8%) to 0.6% (0.3% to 0.9%) |
| Kettunen et al[ | Helsinki, Finland | T | CBVD (ICD‐10: 60 to 61, 63 to 64) | NA | 3265 | 65+ | 16.3 | 1 | −5.9% (−11.9% to 0.5%) to 13.3% (2.3% to 25.5%) |
| Revich and Shaposhnikov [ | Moscow, Russia | T | CBVD (ICD‐10: 60 to 69) | 68.8 | NA | All ages | 34 | 0 | 0.5% (0% to 0.9%) to 0.7% (0.1% to 1.3%) |
| CBVD (ICD‐10: 60 to 69) | 41 | NA | 75+ | 34 | 0 | ||||
| Li et al[ | Tianjin, China | T | CBVD (ICD‐9: 60 to 69) | 21.5 | 111 087 | 65+ | 95 | 0–1 | −0.6% (−2.0% to 0.8%) to 1.0% (0.3% to 1.7%) |
| Romieu et al[ | Multicities,Latin America | T | CBVD (ICD‐10: 60 to 69) | 0.7 to 14.99 | 263 to 43 805 | All | 29.6 to 78.4 | 0–3 | 0.2% (−1.6% to 2.1%) to 2.6% (0.8% to 4.5%) |
| Diaz et al[ | Madrid, Spain | C | CBVD (ICD‐10: 60 to 69) | 4.3 | NA | All | 31.4 | 0, 1, 2, 3, 4 | 1.8% (−0.4% to 4.0%) |
| PM2.5‐10 | |||||||||
| Perez et al[ | Barcelona, Spain | C | CBVD (ICD‐10: 60 to 69) | 3 | 3269 | All ages | 14 | 1, 2, 0–1 | −0.1% (−1.2% to 1.0%) to 8.7% (1.8% to 16.1%) |
| Perez et al[ | Barcelona, Spain | C | CBVD (ICD‐10: 60 to 69) | 3.2 | 1375 | All | 13.5 | 1, 2 | 3.5% (−0.6% to 7.9%) |
| PM2.5+PM10 | |||||||||
| Faustini et al[ | Rome, Italy | C | CBVD (ICD‐9: 430 to 438) | 3.6, 14.5 | 15 884, 8 552 785 | All | PM10 (36.4), PM2.5 (20.2) | 0, 1, 2, 3, 4, 5, 0–1, 2–5, 0–5 | 0.6% (−0.7% to 1.9%) to 1.4% (−0.1% to 2.8%) |
| PM2.5+PM2.5‐10 | |||||||||
| Zanobetti and Schwartz [ | 112 cities, US | T | CBVD (ICD‐10: 60 to 69) | 11.7 | 330 613 | All | NA | 0–1 0–2 | 1.0% (0% to 2.0%) 1.8% (0.9% to 2.6%) |
C indicates case‐crossover; CBVD, cerebrovascular disease; PM, particulate matter; T, time‐series.
Per 10‐μg/m3 increase in pollutant levels.
Figure 2.Summary relative risk (95% CI) for the associations between short‐term exposure to particulate matter PM2.5, PM10, and PM2.5‐10 morality and hospitalization for cerebrovascular disease (CBVD) and hospitalization for ischemic or hemorrhagic stroke.
Figure 3.Individual study relative risk (95% CI) for the association between particulate matter PM2.5 and hospital admissions for cerebrovascular disease (CBVD).[32–33,32–36,39,48–50,52]
Sensitivity Analyses of Summary Relative Risk (95% CI) for the Associations of Particulate Matter (PM) With Cerebrovascular Disease (CBVD), Ischemic Stroke (IS), or Hemorrhagic Stroke (HS)
| Analysis | PM2.5 | PM10 | ||
|---|---|---|---|---|
| Studies Included | Effect Estimate (95% CI) | Studies Included | Effect Estimate (95% CI) | |
| Studies by individual lag subgroups | ||||
| Hospital admission (CBVD) | ||||
| Lag 0 |
[ | 1.000 (0.988 to 1.013) |
[ | 1.001 (0.989 to 1.013) |
| Lag 1 |
[ | 0.997 (0.989 to 1.006) |
[ | 0.999 (0.997 to 1.001) |
| Lag 2 |
[ | 1.001 (0.990 to 1.011) |
[ | 1.000 (0.999 to 1.007) |
| Lag 3 |
[ | 1.002 (0.984 to 1.020) |
[ | 1.002 (0.994 to 1.010) |
| Lag 0–1 |
[ | 0.999 (0.973 to 1.025) |
[ | 0.996 (0.996 to 1.002) |
| Hospital admission (IS) | ||||
| Lag 0 |
[ | 1.066 (0.929 to 1.223) |
[ | 0.994 (0.980 to 1.008) |
| Lag 1 |
[ | 1.016 (0.890 to 1.160) |
[ | 1.007 (0.992 to 1.022) |
| Lag 2 | — | — |
[ | 1.000 (0.973 to 1.027) |
| Lag 3 | — | — |
[ | 1.001 (0.984 to 1.017) |
| Hospital admission (HS) | ||||
| Lag 0 |
[ | 0.990 (0.955 to 1.026) |
[ | 0.995 (0.981 to 1.010) |
| Lag 1 |
[ | 1.035 (0.934 to 1.147) |
[ | 0.999 (0.980 to 1.019) |
| Lag 2 | — | — |
[ | 0.997 (0.977 to 1.017) |
| Lag 3 | — | — |
[ | 1.016 (0.994 to 1.039) |
| Mortality (CBVD) | ||||
| Lag 0 |
[ | 1.011 (1.002 to 1.019) |
[ | 1.006 (1.004 to 1.009) |
| Lag 1 |
[ | 1.006 (0.995 to 1.017) |
[ | 1.007 (1.003 to 1.011) |
| Lag 2 | — | — |
[ | 1.004 (1.000 to 1.008) |
| Lag 0–1 |
[ | 1.012 (1.004 to 1.019) | — | — |
| Excluding studies using a subset of ICD‐10 codes to define CBVD | ||||
| Hospital admission |
[ | 1.002 (0.995 to 1.009) |
[ | 1.006 (0.994 to 1.017) |
| Mortality |
[ | 1.004 (1.000 to 1.008) |
[ | 1.015 (1.007 to 1.022) |
| Excluding studies using administrative data for case ascertainment | ||||
| Hospital admission (IS) |
[ | 0.994 (0.967 to 1.022) |
[ | 0.972 (0.927 to 1.018) |
| Studies by geographic locations | ||||
| Hospital admission (CBVD) | ||||
| Europe |
[ | 0.987 (0.972 to 1.002) |
[ | 1.003 (0.995 to 1.011) |
| East Asia |
[ | 1.009 (1.003 to 1.016) |
[ | 1.002 (0.996 to 1.009) |
| Latin America | — | — |
[ | 1.014 (1.005 to 1.023) |
| North America |
[ | 1.010 (1.003 to 1.017) |
[ | 1.009 (0.989 to 1.008) |
| Australia |
[ | 0.969 (0.937 to 1.003) |
[ | 0.984 (0.960 to 1.008) |
| Hospital admission (IS) | ||||
| Europe |
[ | 0.971 (0.846 to 1.115) |
[ | 0.977 (0.931 to 1.025) |
| East Asia |
[ | 0.932 (0.864 to 1.005) |
[ | 1.017 (0.969 to 1.067) |
| Latin America | — | — | — | — |
| North America |
[ | 1.039 (0.977 to 1.104) |
[ | 1.003 (0.994 to 1.012) |
| Australia | — | — | — | — |
| Hospital admission (HS) | ||||
| Europe | — | — |
[ | 0.901 (0.731 to 1.111) |
| East Asia |
[ | 0.990 (0.954 to 1.028) |
[ | 1.016 (0.960 to 1.075) |
| Latin America | — | — | — | — |
| North America |
[ | 0.984 (0.857 to 1.130) |
[ | 0.998 (0.978 to 1.019) |
| Australia | — | — | — | — |
| Mortality (CBVD) | ||||
| Europe |
[ | 1.014 (1.000 to 1.028) |
[ | 1.005 (1.001 to 1.009) |
| East Asia |
[ | 1.013 (1.002 to 1.024) |
[ | 1.005 (1.003 to 1.008) |
| Latin America | — | — |
[ | 1.004 (1.003 to 1.005) |
| North America |
[ | 1.015 (1.007 to 1.022) | — | — |
| Australia | — | — | — | — |
Figure 4.A, Funnel plot of individual study relative risk (95% CI) for the association between particulate matter PM2.5 and hospital admissions for cerebrovascular disease (CBVD); (B) after applying trim and fill methods to adjust for publication bias.
Figure 5.Individual study relative risk (95% CI) for the association between particulate matter PM2.5 and hospital admissions for ischemic stroke.[32,34,37,40,59,61]
Figure 6.Funnel plot of individual study relative risk (95% CI) for the association between particulate matter PM2.5 and hospital admissions for ischemic stroke.
Figure 7.Individual study relative risk (95% CI) for the association between particulate matter PM2.5 and hospital admissions for hemorrhagic stroke.[32,37]
Figure 8.Funnel plot of individual study relative risk (95% CI) for the association between particulate matter PM2.5 and hospital admissions for hemorrhagic stroke.
Figure 9.Individual study relative risk (95% CI) for the association between particulate matter PM2.5 and mortality for cerebrovascular disease (CBVD).[41,70–72,77]
Figure 10.Funnel plot of individual study relative risk (95% CI) for the association between particulate matter PM2.5 and mortality for cerebrovascular disease (CBVD).
Figure 11.Individual study relative risk (95% CI) for the association between particulate matter PM10 and hospital admissions for cerebrovascular disease (CBVD).[8,32,36,45–53]
Figure 12.Funnel plot of individual study relative risk (95% CI) for the association between particulate matter PM10 and hospital admissions for cerebrovascular disease (CBVD).
Figure 13.Individual study relative risk (95% CI) for the association between PM10 and hospital admissions for ischemic stroke.[32,37,42,57–58,57–63]
Figure 14.A, Funnel plot of individual study relative risk (95% CI) for the association between particulate matter PM10 and hospital admissions for ischemic stroke; (B) After applying trim and fill methods to adjust for publication bias.
Figure 15.Individual study relative risk (95% CI) for the association between particulate matter PM10 and hospital admissions for hemorrhagic stroke.[32,37,42,58,63]
Figure 16.Funnel plot of individual study relative risk (95% CI) for the association between particulate matter PM10 and hospital admissions for hemorrhagic stroke.
Figure 17.Individual study relative risk (95% CI) for the association between particulate matter PM10 and mortality for cerebrovascular disease (CBVD).[41,43,64–69,74,76–77]
Figure 18.A, Funnel plot of individual study relative risk (95% CI) for the association between particulate matter PM10 and mortality for cerebrovascular disease (CBVD); (B) After applying trim and fill methods to adjust for publication bias.
Figure 19.Individual study relative risk (95% CI) for the association between particulate matter PM2.5‐10 and hospital admissions for cerebrovascular disease (CBVD).[36,39,50,52]
Figure 20.Funnel plot of individual study relative risk (95% CI) for the association between particulate matter PM2.5‐10 and hospital admissions for cerebrovascular disease (CBVD).
Figure 21.Individual study relative risk (95% CI) for the association between particulate matter PM2.5‐10 and mortality for cerebrovascular disease (CBVD).[70,73,75]
Figure 22.Funnel plot of individual study relative risk (95% CI) for the association between particulate matter PM2.5‐10 and mortality for cerebrovascular disease (CBVD).